# Alexion Pharmaceuticals, Inc. clinical trials: 255 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 255 trials with Alexion Pharmaceuticals, Inc. as lead sponsor, 21 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Alexion Pharmaceuticals, Inc.: 255 rows for $12.75, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/alexion-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 255
- Recruiting or not yet: 21
- Read on: November 19, 2026

## Trials

The 25 newest of 255, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 28, 2026 | NCT07789483 | An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy | Alexion Pharmaceuticals, Inc. | Phase 3 | Not yet recruiting | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 1,180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789483) |
| July 28, 2026 | NCT07732361 | A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic... | Alexion Pharmaceuticals, Inc. | Observational | Completed | Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplant | 307 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732361) |
| May 19, 2026 | NCT07596784 | Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) | Alexion Pharmaceuticals, Inc. | Phase 3 | Recruiting | Generalized Myasthenia Gravis, gMG | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07596784) |
| April 29, 2026 | NCT07557420 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica... | Alexion Pharmaceuticals, Inc. | Phase 3 | Recruiting | NMOSD, Neuromyelitis Optica Spectrum Disorder | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07557420) |
| February 17, 2026 | NCT07413679 | Long-term Safety of Danicopan: IPIG Registry-based Cohort Study | Alexion Pharmaceuticals, Inc. | Observational | Active not recruiting | Paroxysmal Nocturnal Hemoglobinuria, PNH | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07413679) |
| February 17, 2026 | NCT07413250 | Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data | Alexion Pharmaceuticals, Inc. | Observational | Active not recruiting | Paroxysmal Nocturnal Hemoglobinuria, PNH | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07413250) |
| January 20, 2026 | NCT07352423 | Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants | Alexion Pharmaceuticals, Inc. | Phase 1 | Recruiting | Healthy Adult Participants | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07352423) |
| December 29, 2025 | NCT07308574 | Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS | Alexion Pharmaceuticals, Inc. | Phase 4 | Recruiting | aHUS, Atypical Hemolytic Uremic Syndrome | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07308574) |
| December 29, 2025 | NCT07306949 | Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers | Alexion Pharmaceuticals, Inc. | Phase 4 | Recruiting | Transthyretin-type Cardiac Amyloidosis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07306949) |
| October 28, 2025 | NCT07221838 | A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab | Alexion Pharmaceuticals, Inc. | Phase 4 | Recruiting | Generalized Myasthenia Gravis, gMG | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221838) |
| October 20, 2025 | NCT07218887 | ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy | Alexion Pharmaceuticals, Inc. | Phase 1/2 | Recruiting | BAG3 Mutation Associated Dilated Cardiomyopathy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07218887) |
| September 8, 2025 | NCT07160608 | Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | Alexion Pharmaceuticals, Inc. | Phase 2 | Active not recruiting | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07160608) |
| September 5, 2025 | NCT07157787 | Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) | Alexion Pharmaceuticals, Inc. | Phase 2 | Recruiting | Primary Membranous Nephropathy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07157787) |
| July 23, 2025 | NCT07081646 | A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. | Alexion Pharmaceuticals, Inc. | Phase 1/2 | Recruiting | Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07081646) |
| June 25, 2025 | NCT07037420 | ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly | Alexion Pharmaceuticals, Inc. | Phase 2 | Terminated | Acromegaly | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037420) |
| June 17, 2025 | NCT07024563 | Study of Ravulizumab in Pediatric Participants With Primary IgAN | Alexion Pharmaceuticals, Inc. | Phase 3 | Recruiting | IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis, Henoch-schonlein Purpura... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07024563) |
| May 13, 2025 | NCT06967480 | Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis | Alexion Pharmaceuticals, Inc. | Observational | Recruiting | Generalized Myasthenia Gravis, Anti-AChR Antibody Positive | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06967480) |
| February 17, 2025 | NCT06830798 | Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered... | Alexion Pharmaceuticals, Inc. | Phase 3 | Recruiting | Delayed Graft Function, DGF, Kidney Transplant | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06830798) |
| January 8, 2025 | NCT06764160 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG | Alexion Pharmaceuticals, Inc. | Phase 3 | Completed | Generalized Myasthenia Gravis (gMG), Refractory gMG | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06764160) |
| December 20, 2024 | NCT06744647 | Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation | Alexion Pharmaceuticals, Inc. | Phase 2 | Active not recruiting | Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06744647) |
| December 9, 2024 | NCT06724809 | Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD | Alexion Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | NMOSD, Neuromyelitis Optica Spectrum Disorders | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06724809) |
| November 6, 2024 | NCT06677138 | PK Study of Gefurulimab SC in Healthy Chinese Adult Participants | Alexion Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06677138) |
| September 23, 2024 | NCT06607627 | PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | Alexion Pharmaceuticals, Inc. | Phase 3 | Recruiting | Generalized Myasthenia Gravis, gMG | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06607627) |
| August 30, 2024 | NCT06578949 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal... | Alexion Pharmaceuticals, Inc. | Phase 3 | Completed | Paroxysmal Nocturnal Hemoglobinuria, PNH | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06578949) |
| June 7, 2024 | NCT06449001 | Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant... | Alexion Pharmaceuticals, Inc. | Phase 3 | Recruiting | Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06449001) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 67 |
| Phase 1/2 | 13 |
| Phase 2 | 61 |
| Phase 2/3 | 7 |
| Phase 3 | 54 |
| Phase 4 | 9 |
| Not applicable | 9 |
| Observational | 35 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 153 |
| Terminated | 45 |
| Recruiting | 20 |
| Active not recruiting | 20 |
| Withdrawn | 7 |
| No longer available | 5 |
| Approved for marketing | 2 |
| Enrolling by invitation | 1 |
| Available | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hemoglobinuria, Paroxysmal | 32 |
| Hypophosphatasia | 23 |
| Atypical Hemolytic Uremic Syndrome | 16 |
| Myasthenia Gravis | 16 |
| Rickets | 13 |
| Osteomalacia | 13 |
| Wolman Disease | 12 |
| Bone Diseases | 12 |
| Hepatolenticular Degeneration | 11 |
| Cholesterol Ester Storage Disease | 9 |
| Neuromyelitis Optica | 9 |
| Lysosomal Storage Diseases | 7 |
| Thrombotic Microangiopathies | 6 |
| Hemolysis | 6 |
| Immunoglobulin Light-chain Amyloidosis | 5 |
| Mucopolysaccharidosis III | 5 |
| Glomerulonephritis, IGA | 5 |
| Recurrence | 5 |
| Glomerulonephritis, Membranoproliferative | 4 |
| HIV Infections | 4 |
| Myelitis, Transverse | 4 |
| Optic Neuritis | 4 |
| Demyelinating Diseases | 4 |
| Hepatitis B, Chronic | 3 |
| COVID-19 | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Whiskey bars in the United States](https://specstream.ai/data/businesses/whiskey-bars/united-states)
- [Auto lenders in the United States](https://specstream.ai/data/businesses/auto-lenders/united-states)
- [Belgian restaurants in the United States](https://specstream.ai/data/businesses/belgian-restaurants/united-states)
- [Chiropractic clinics in the United States](https://specstream.ai/data/businesses/chiropractic-clinics/united-states)
- [Disability law firms in the United States](https://specstream.ai/data/businesses/disability-law-firms/united-states)
